Johannes Drach

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

Shaji Kumar, J H Lee, Juan José Lahuerta et al. · Leukemia · 2011 · 721 citations

Medicine, Hematology, Pharmacotherapy +15

Genetics and Cytogenetics of Multiple Myeloma

Rafaël Fonseca, Bart Barlogie, Régis Bataille et al. · Cancer Research · 2004 · 686 citations

Medicine, Genetics, Molecular Genetics +17

D-Dimer and Prothrombin Fragment 1 + 2 Predict Venous Thromboembolism in Patients With Cancer: Results From the Vienna Cancer and Thrombosis Study

Cihan Ay, Rainer Vormittag, Daniela Dunkler et al. · Journal of Clinical Oncology · 2009 · 428 citations · Full text

Medicine, Hematology, Oncology +17

Bortezomib-Based Therapy for Newly Diagnosed Mantle-Cell Lymphoma

Tadeusz Robak, Huiqiang Huang, Jie Jin et al. · New England Journal of Medicine · 2015 · 385 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Single-Agent Lenalidomide in Patients With Mantle-Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib: Phase II MCL-001 (EMERGE) Study

André Goy, Rajni Sinha, Michael E. Williams et al. · Journal of Clinical Oncology · 2013 · 349 citations · Full text

Medicine, Oncology, Pharmacotherapy +17